Friday, May 20, 2022
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | Business | Optimus Granted Dcgi Nod For Restricted Emergency Use Of Molnupiravir

Optimus granted DCGI nod for restricted emergency use of molnupiravir

By Telangana Today
Published: Updated On - 05:08 PM, Tue - 28 December 21

Hyderabad: Hyderabad-based Optimus Pharma launched their frontline Covid-19 medication molnupiravir in the Indian market, as they have received permission for the restricted emergency use for Covid-19 drug.

Optimus Pharma is ready with a commercial quantity of the drug. The company has completed its phase 3 clinical trials on 1,218 subjects across 29 geographical study sites all over India.

“We wanted to cover maximum demographic diversity into our trial in order to obtain data across the different geographical regions of the country and conclusive evidence that Molnupiravir is able to bring about viral load reduction over five days of treatment duration,” said Optimus Pharma CMD Dr D Srinivasa Reddy.

Optimus Pharma has developed the bulk drug in-house at its R&D centre in Hyderabad. Molnupiravir is administered as an 800 mg dose by orally consuming four capsules of 200mg twice a day. Upon oral administration, Molnupiravir, being a prodrug, is metabolised into its active form and converted into its triphosphate (TP) form.

The TP form of Molnupiravir is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription thereby significantly reducing viral replication.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .


  • Follow Us :
  • Tags
  • Drug Controller General of India
  • Molnupiravir
  • Optimus Pharma

Related News

  • Hetero presents positive results from Molnupiravir phase III trials

  • Dr Reddy’s strengthening Covid portfolio

  • ICMR team says no to anti-Covid pill Molnupiravir

  • Molnupiravir has no observed safety concerns: MSD India

  • MSN set to launch molnupiravir generic drug for Covid-19 treatment

  • Dr Reddy’s to launch molnupiravir next week at Rs 35 per capsule

Latest News

  • Two of family electrocuted in Rajanna-Sircilla

    49 seconds ago
  • Google says Android 13 Beta to have support for braille displays

    3 mins ago
  • Lalu, daughter Misa raided by CBI in ‘land for job’ scam

    14 mins ago
  • Twitter’s new policy to hide tweets with false information during crisis

    29 mins ago
  • Global Covid caseload tops 523.9 million: Johns Hopkins University

    36 mins ago
  • CM KCR embarks on ‘national mission’

    9 hours ago
  • I want to dedicate this victory to all Indians: Telangana’s Nikhat Zareen

    9 hours ago
  • Opinion: Life within Dark Media

    9 hours ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam